News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
no_data1SEC crypto safe harbor heads to White House review, proposal due 'shortly' says Atkins2Nvidia CoWoS production capacity to reach 650,000 units in 2026, up 76% year-on-year; 840,000 units in 2027. Next-generation Rubin GPU mass production target lowered from 2 million to 1.5 million units due to HBM4 validation delays.3Geopolitical Pause or Rising Tensions? Markets Brace for Iran's Critical Deadline
Flash
21:42
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals has reached an agreement to acquire the asset portfolio related to the candidate drug NV-5138 (also known as SPN-820).The subject of this transaction covers not only the core intellectual property rights of the drug, but also its existing inventory. This move marks an important step forward in Supernus Pharmaceutical's strategy to expand its product pipeline.
21:41
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals officially signed an asset purchase agreement with Navitor on April 1, 2026.This move marks a significant milestone for both companies in asset trading.
21:41
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), the purchase price structure for Supernus Pharmaceuticals not only includes the ongoing Phase 2B clinical research, but also potential future milestone payments, with the total amount reaching up to $350 million.This arrangement highlights the high recognition of the future potential of the relevant asset in this transaction. Milestone payments are usually linked to key milestones in the R&D process or future commercialization results. The potential maximum payment of up to $350 million in this case undoubtedly sends a positive signal to the market regarding the asset's prospects.
Trending news
MoreTop 20 Active U.S. Stocks in Overnight Trading: April 7, 2026
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), the purchase price structure for Supernus Pharmaceuticals not only includes the ongoing Phase 2B clinical research, but also potential future milestone payments, with the total amount reaching up to $350 million.
News